CD19 and diffuse large B-cell lymphoma: Finally, in a case report, a 68-year-old DLBCL patient treated with four previous lines of therapy remain in CR at 21 months follow-up with no ICANS, GVHD, or CRS when treated with CD19-targeting CAR T cells bearing TRAC and PD-1 KO [245].